pyrazines has been researched along with camostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fätkenheuer, G; Malin, JJ; Rybniker, J; Simonis, A; Theobald, SJ | 1 |
| Banerjee, DI; Darji, SA; Lipsa Rath, S; Toor, HG | 1 |
1 review(s) available for pyrazines and camostat
| Article | Year |
|---|---|
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guanidines; Guanine; Humans; Indoles; Lopinavir; Protease Inhibitors; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Virus Internalization; Virus Replication | 2021 |
1 other study(ies) available for pyrazines and camostat
| Article | Year |
|---|---|
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
Topics: Amides; Anti-Bacterial Agents; Antiviral Agents; Binding Sites; COVID-19 Drug Treatment; Drug Repositioning; Esters; Gabexate; Guanidines; Molecular Docking Simulation; Phytochemicals; Protein Binding; Pyrazines; Raltegravir Potassium; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Stavudine; Tenofovir | 2021 |